Lerøy invests in US biotech firm

The terms of the investment remain undisclosed.

“This collaboration between Salmonics and Lerøy will usher in new opportunities to expand the use of our fish blood-based biomedical products into the biotechnology and pharmaceutical space globally,” Salmonics President and CEO Cem Giray said.

He continued: “Lerøy’s expertise and commitment to sustainability align perfectly with our mission to transform aquaculture and fisheries byproducts into valuable biotechnology, pharmaceutical, and research resources to improve patient care and outcomes while potentially lowering healthcare costs with a net positive environmental impact.”

According to Salmonics, Lerøy’s investment will provide the company with the resources to accelerate its product development and market reach.

“We are excited and pleased to support the work Salmonics has undertaken to advance cutting-edge biotechnological solutions utilizing farmed fish, increasing value and meeting our sustainable development goals,” Lerøy CEO Henning Beltestad said. “This investment reflects our commitment to innovative solutions that enhance the efficiency and potential of the seafood value chain while delivering positive benefits to healthcare.”

Salmonics develops and markets reagents and biomedical products from the blood of salmon and other fish species. Its proteins and reagents support a wide range of applications, including in regenerative medicine, cell proliferation, clotting, wound care and pain treatment.

Headquartered in Bergen, Norway, Lerøy is a global seafood leader with approximately 6,000 employees, industrial and distribution activity in 15 countries and sales to more than 80 markets worldwide. The company handles up to 400,000 tonnes of seafood annually.